Doctors use molecular responses to monitor the effectiveness of CML treatment. A major molecular response is when the amount of the abnormal BCR–ABL gene in your blood and bone marrow is lowered ...

Early molecular response (EMR, BCR-ABL1 (IS)⩽10% at 3 months) is a strong predictor of outcome in imatinib-treated chronic phase chronic myeloid leukemia (CP-CML) patients, but for patients who ...

HOUSTON -- An early molecular or cytogenetic response correlated with better long-term survival in heavily pretreated chronic-phase chronic myeloid leukemia (CML) treated with the BCR-ABL ...

Early molecular response in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) treated with dasatinib (DAS) or imatinib (IM) from DASISION. Neil P. Shah , Giuseppe Saglio , Andreas ...

Similarly, a major molecular response has been reached in 32 of 65 patients (63%) in the nilotinib trial, with 12 patients (24%) achieving complete molecular response.

Early response to ponatinib appeared predictive of survival among certain patients with chronic myeloid leukemia, according to findings presented at Society of Hematologic Oncology Annual Meeting ...

Results: Early molecular response of BCR-ABL% (IS) ≤ 10 occurred in 19% of pts who received nilotinib. Pts with BCR-ABL% (IS) >1 – ≤10 ... Association of early molecular response to nilotinib with ...

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML) B Hanfstein M C Müller ...

BCR-ABL1 Levels Can Predict Sustained Deep Molecular Response in CML —In CML, sustained deep molecular response opens the possibility of treatment discontinuation. Share on Facebook.

On the second day at the Annual Meeting of the American Society of Hematology 2014, Francois-Xavier Mahon, MD, PhD, Bordeaux Hospital, INSERM 1035, Bordeaux, France, shared the results from the ...

HOLLYWOOD, Florida — Give it 3 months, but if a patient with chronic myelogenous leukemia (CML) has a suboptimal response to therapy with a first-line tyrosine kinase inhibitor (TKI), it's not ...

Presented at ASH were the five-year ENESTnd data, which continued to support the use of Tasigna in newly diagnosed Ph+ CML patients and demonstrated higher rates of early and deeper sustained ...